Drug news
CHMP recommends Tresiba for children/adolescents with Diabetes- Novo Nordisk
Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba (insulin degludec) in children and adolescents aged 1-17 years with Diabetes. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Tresiba to children with type 1 and type 2 Diabetes. According to the International Diabetes Federation, an estimated 497,100 children are living globally with type 1 Diabetes and rates of type 2 Diabetes among children are also on the increase.